British biotech Shire (NSDQ:SHPGY) is under investigation by the U.S. Justice Dept. for marketing practices for its Dermagraft diabetic foot ulcer treatment, according to regulatory filings.
Wall Street Beat
Accuray’s CyberKnife goes head-to-head against Intuitive’s da Vinci robot
Asahi closes 2nd phase of $2.2B Zoll buyout
New J&J CEO Gorsky wants to grow device business | Wall Street Beat
When Alex Gorsky takes the helm at Johnson & Johnson (NYSE:JNJ) tomorrow, he’ll become responsible for a company bedeviled by a series of high-profile, big-ticket recalls, a more than $1 billion legal settlement – and blessed with the world’s largest medical device business.
NASDAQ halts trading in HeartWare shares ahead of FDA panel vote
Early indications that the FDA is likely to approve an implantable heart pump made by HeartWare International (NSDQ:HTWR) pushed its shares up nearly 7% this week, prompting the NASDAQ stock exchange to halt trading of the shares today as an agency panel considers the company’s pre-market approval application.
Edwards’ Sapien sales spike 67% during 1st quarter on U.S. market
Shares of Edwards Lifesciences (NYSE:EW) got a little boost on Wall Street after the company posted a 67% spike in Sapien sales during its 1st quarter.
The Irvine, Calif.-based med-tech titan posted $459.2 million in sales during the 3 months ended March 31, a 13.5% increase from he $404.5 million in revenues posted during the same period last year.
MassDevice.com +3 | The top 3 med-tech stories for April 24, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Analysts cautious on Boston Scientific’s $1.3B lead-free ICD ahead of FDA panel
Study results released ahead of an FDA panel review for Boston Scientific (NYSE:BSX) subsidiary Cameron Health’s lead-free subcutaneous implantable cardioverter defibrillator has some Wall Street analysts wondering whether a substantial market exists for the devices.
Orthofix sells Breg sports medicine unit to PE firm for $158M cash
MassDevice.com +3 | The top 3 med-tech stories for April 23, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
HeartWare stock gains 4.5% as analysts predict FDA approval ahead of panel meeting
Despite FDA concerns, analysts expect a positive vote for HeartWare International‘s (NSDQ:HTWR) HVAD ventricular assist system as a bridge to transplant for patients with end-stage heart failure.